A single dose of ibuprofen provides better pain relief than acetaminophen or codeine for children requiring emergency treatment for musculoskeletal trauma, results of a randomized, controlled trial demonstrate.
Although studies have compared the effects of oral analgesia in postoperative pediatric patients, this was the first randomized, controlled trial to compare the effects of common pain medications in children treated for acute musculoskeletal injury. The study objective was to determine which pain medication given as a single oral dose provided the most effective analgesia in this patient population.
The study included 336 patients aged 6 to 17 years presenting to the emergency department of Children's Hospital of Eastern Ontario with pain from a musculoskeletal injury to the extremities, neck, or back that occurred ≤48 hours of arrival at the emergency department. Patients were excluded if they required resuscitation, had an open fracture, had an intravenous line in place, had received acetaminophen or codeine within the previous 4 hours or ibuprofen within the previous 6 hours, had significant cognitive impairment, or had a contraindication to one of the study drugs.
There was no significant difference in pain score change between the treatment groups at 30 minutes; at 60 minutes and onward, ibuprofen was associated with significantly greater improvements in pain scores. At 60 minutes, patients who received ibuprofen had a mean 24-point pain score reduction compared with a 12-point reduction for patients who received acetaminophen and an 11-point reduction for patients who received codeine (P<.001). There was no significant difference between the acetaminophen and codeine groups throughout the study time period. The advantage for ibuprofen also was significant after 90 minutes (P=.001) and at 120 minutes (P=.004).
The number of children achieving adequate analgesia at 60 minutes was also significantly higher in the ibuprofen group compared with the acetaminophen and codeine groups (P<.001). Additional analgesic was administered to 22.2% of the children in the codeine group, 15.6% in the acetaminophen group, and 14.3% in the ibuprofen group, a nonsignificant difference (P=.32).
SOURCE
Clark E, Plint AC, Correll R, Gaboury I, Passi B. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma. Pediatrics. 2007;119;460–467.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More